

December 04, 2025

Rossari Biotech Limited: Ratings reaffirmed and assigned for enhanced amount

Summary of rating action

Instrument*	Previous rated amount (Rs. crore)	Current rated amount (Rs. crore)	Rating action
LT – Fund based – Working capital facilities	172.00	240.00	[ICRA]AA- (Positive); reaffirmed & assigned for enhanced amount
LT – Fund based – Term loan	35.00	60.00	[ICRA]AA- (Positive); reaffirmed & assigned for enhanced amount
ST- Fund based – WCDL-interchangeable	(20.00)	(20.00)	[ICRA]A1+; reaffirmed
ST – Non-fund based limits	25.61	23.31	[ICRA]A1+; reaffirmed
LT/ST – Unallocated limits	10.00	10.00	[ICRA]AA- (Positive)/ [ICRA]A1+; reaffirmed
Total	242.61	333.31	

*Instrument details are provided in Annexure I

Rationale

For arriving at the ratings, ICRA has taken a consolidated view of Rossari Biotech Limited (RBL), and its subsidiaries enumerated in Annexure II on account of the strong operational, managerial and financial linkages among the entities.

The Positive outlook factors in the expectation of a healthy ramp-up in the company's revenue and profitability, going forward, supported by a steady demand for its products and expansion of the ethoxylation capacity under Unitop Chemicals Private Limited (rated [ICRA]AA- (Positive)/[ICRA]A1+). The company continues to witness healthy demand from its end-user industries, particularly home, personal care and performance chemicals, while it is expanding its distribution network in the textile chemical segment. The capacity expansion under Unitop Chemicals Private Limited includes additional ethoxylation capacity of 30,000 MTPA to meet the growing demand in agrochemicals, home and personal care, oil & gas and the pharma sector. Of this planned addition, 15,000 MTPA was commissioned as of September 2025, while the remaining 15,000 MTPA is expected to be operational by the end of Q3 FY2026. The company has also set up a 20,000-MTPA capacity (commissioned in September 2025) to produce specialty chemicals, including the raw materials used by other Group companies.

The ratings continue to factor in the extensive experience of RBL in the specialty chemical manufacturing business spanning around two decades and the established track record of its management. The ratings also consider the strong financial profile of RBL, characterised by healthy profitability and the low reliance on external borrowings, resulting in comfortable gearing and coverage indicators.

The ratings also factor in the company's robust in-house research and development (R&D) facilities, aided by the expertise of Unitop Chemicals Private Limited and Tristar Intermediates Private Limited in complementary chemistries and the synergistic business opportunities through them, enabling cross-selling and expanding the Group's market reach.

The ratings are, however, constrained by competition in the specialty chemicals segment, both from domestic and prominent multinational companies. These competitive pressures impose constraints on the company's customer dynamics, as they may limit its flexibility in pricing and potentially impact the profitability. Though raw material costs are stable at present, the inherent volatility in prices remains a key monitorable as it directly affects the company's profitability, even as RBL may be able to partially pass on the cost increase to customers.

ICRA notes that the company is undertaking a total capex of Rs. 192 crore. The funding for the entire capex has been tied up and given the healthy internal cash generation, the coverage metrics should remain healthy. However, the Group remains

exposed to project execution risks, given the size of the capex. The timely commissioning of the projects within the estimated capital outlay and the subsequent ramp-up of the operational performance will remain a key monitorable, going forward.

The Positive outlook reflects ICRA's opinion that the overall scale of operation is expected to witness a healthy improvement, driven by a steady demand for its products and the additional revenue from the upcoming capex plans once commissioned.

Key rating drivers and their description

Credit strengths

Experienced management and established market position with diversified product portfolio - The promoters of RBL are technocrats with extensive experience in the chemical industry spanning over three decades. The company is a well-established player in the specialty chemical business and caters to three broad segments: i) Textile specialty chemicals (TSC) ii) Home, personal care and performance chemicals (HPPC) and iii) Animal health and nutrition (AHN). The Rossari Group has a large and diversified product portfolio catering to various end-user industries. The acquisition of Unitop Chemicals Private Limited, Tristar Intermediates Private Limited and Romakk Chemicals Private Limited provided synergistic benefits and enabled the company to widen its product offerings.

Strong R&D facilities for new product development and process innovation - While the company had in-house R&D capabilities, the recent acquisitions have augmented the Group's R&D capabilities in both current and new chemistries, which will aid new product development. The new products being developed include green products in the TSC segment, nanotechnology-based cleaning products and water treatment chemicals.

Established relationship with wide customer base of distributors and institutional customers - The company has a wide customer base of over 500 clients, comprising reputed institutional players and distributors. The company has maintained long-term relationships with several customers, receiving repeat orders and, in several cases, supplying customised products, which improved the client stickiness. The company's exports have also increased, and it is exploring new customer segments and channels. The developments on this front will be monitored.

Strong financial risk profile - The company witnessed a healthy revenue growth of ~14% in FY2025 and H1 FY2026 on a consolidated basis, aided by the robust performance of the subsidiaries. The overall profitability has remained robust due to stable raw material prices along with a healthy growth in volumes. The debt levels remain moderately low, resulting in a healthy credit profile with TD/OPBDITA at 0.82 times and interest coverage at 14.8 times in FY2025.

Credit challenges

Susceptible to volatility in sharp raw material price fluctuations and forex movements - The company's profitability remains vulnerable to the volatility in raw material prices and foreign currency exchange rate fluctuations. The company's key raw materials include acrylic acid, acetic acid, silicone oil, etc., whose prices are linked to crude oil and are inherently volatile in nature. Although the prices of raw materials have stabilised in FY2025, the inherent price volatility remains a critical aspect to monitor as the company's profitability is contingent upon the stability of raw material costs. However, the company's ability to pass on a portion of the cost increase to customers provides some potential cushion.

Moreover, imports contribute ~14% to its raw material consumption; however, the company is largely protected against forex risks owing to a natural hedge provided by the exports exceeding the imports undertaken. ICRA takes note of the steps taken by the company to reduce imports through the procurement of raw material from local players, while at the same time exports are increasing, leading to an improvement in the natural hedge.

Intense competition - The company faces competition from domestic and international players, which limits the pricing flexibility and restricts the margin to an extent in several segments.

Project execution risk arising from capex plan - The Group has a capex plan for incremental ethoxylation capacity to meet the growing demand for products and for backward integration for producing ingredients for its subsidiary companies. The capex plan exposes the company to execution risks in the near to medium term and puts some pressure on the leverage levels and other credit metrics.

Environmental and social risks

Environmental considerations - As a chemical manufacturing company, RBL is exposed to environmental regulations and safety standards, which are expected to be tightened over time. These necessitate investments towards meeting the evolving standards. As per the disclosures, the company complies with the provisions of the relevant standards. Both plants of the company have also been certified by the Zero Discharge Hazardous Chemicals (ZDHC) level 3 certification. Apart from this, the company has made significant investments for measures which include the installment of a sewage treatment plant at Silvassa and a water recycling process at Dahej. ICRA also takes note of the company's efforts for new product development with focus on sustainability. The company's ability to comply with the evolving standards and the success of new product development efforts will be a rating driver from a long-term credit perspective.

Social considerations - Being a chemical manufacturing company, the exposure to on-site health/safety related risks remains high. The company mitigates the risk by adhering to the stipulated healthy and safety regulations/protocols and installation of air pollution control measure devices. Nonetheless, operational incidents leading to injuries etc. continue to be reputational risks. While the company remains exposed to the mentioned social risk, it does not materially affect its credit profile.

Liquidity position: Adequate

The Group's liquidity is expected to remain adequate, given the comfortable debt repayments of ~Rs. 16 crore in FY2026 and ~Rs. 44 crore in FY2027 because of a long-tenor loan availed by the company vis-à-vis its healthy cash accruals. The liquidity is also supported by free cash balance of ~Rs. 103 crore as on March 31, 2025, the largely unutilised working capital limits of Rs. 172 crore, a moderate working capital intensity and stable cash flow from operations. The company may incur an outflow of ~Rs. 88 crore for the remaining payout to acquire the remaining stake in Unitop Chemicals Private Limited in FY2026, which ICRA expects it to meet comfortably amid the long-term debt tie-up for its modest capex requirements.

Rating sensitivities

Positive factors- A sustained improvement in the revenue and margins of the company resulting in sharp improvement in the credit profile may lead to a rating upgrade. A specific credit metric that may lead to a rating upgrade will be TD/OPBDITA<1.0x on a sustained basis.

Negative factors- A sustained moderation in the revenue, profitability and/or a stretch in the working capital cycle thereby leading to weakening of the credit and liquidity profile may result in a rating downgrade.

Analytical approach

Analytical approach	Comments
Applicable rating methodologies	Corporate Credit Rating Methodology Chemicals
Parent/Group support	Not Applicable
Consolidation/Standalone	For arriving at the ratings, ICRA has considered the consolidated financials of Rossari. The subsidiaries and JVs of Rossari that have been considered are enlisted in Annexure II

About the company

Rossari Biotech Ltd was established as a partnership firm, named Rossari Labtech, in 2003 by Mr. Edward Menezes and Mr. Sunil Chari. It was subsequently rechristened Rossari Biotech Limited and converted to a limited company in 2009. On July 23, 2020, the company got listed on the BSE and the NSE. Rossari Biotech Limited is engaged in the manufacturing of speciality chemicals with focus on three business verticals - home, personal care and performance chemicals (HPPC), textile speciality chemicals (TSC) and animal health and nutrition (AHN).

Within the three verticals, it has over 4,250 products catering to diverse end-user industries. Its manufacturing facility is at Silvassa, with an annual installed capacity of 1,20,000 MTPA. It has also set up a new unit at Dahej with an annual capacity of 1,32,500 MTPA, which was fully operational by March 2021. Further, a capacity of 20,000 MTPA was added to the Dahej facility, which was commissioned in September 2025, taking the total installed capacity at Dahej to 152,500 MTPA. It also has two state-of-the-art R&D laboratories at its Silvassa plant and IIT Mumbai. The promoters of the company are technocrats and have extensive experience of over 25 years in the chemical industry.

Rossari Biotech Ltd acquired Tristar Intermediates Private Limited and Unitop Chemicals Private Limited, along with a strategic investment in Romakk Chemicals Private Limited in FY2022, providing synergistic benefits in terms of the diverse end-user industries.

Key financial indicators (audited)

Rossari Biotech Limited (Consolidated)	FY2024	FY2025	H1 FY2026*
Operating income	1,830.6	2,080.29	1,129.82
PAT	130.5	135.4	69.5
OPBDIT/OI	13.6%	12.7%	12.4%
PAT/OI	7.1%	6.51%	6.1%
Total outside liabilities/Tangible net worth (times)	0.5	0.6	0.7
Total debt/OPBDIT (times)	0.5	0.8	1.3
Interest coverage (times)	12.9	14.9	11.8

Source: Company, ICRA Research; * Provisional numbers; All ratios as per ICRA's calculations; Amount in Rs. crore PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Current (FY2026)			Chronology of rating history for the past 3 years							
			FY2026		FY2025		FY2024		FY2023	
Instrument	Type	Amount rated (Rs. crore)	Date	Rating	Date	Rating	Date	Rating	Date	Rating
Working capital	Long term	240.00	Dec-04-2025	[ICRA]AA-(Positive)	Oct-24-2024	[ICRA]AA-(Positive)	July-26-2023	[ICRA]AA-(Stable)	Sept-9-22	[ICRA]AA-(Stable)
Term loan	Long term	60.00	Dec-04-2025	[ICRA]AA-(Positive)	Oct-24-2024	[ICRA]AA-(Positive)	July-26-2023	[ICRA]AA-(Stable)	-	-
Unallocated limit	Long term	10.00	Dec-04-2025	[ICRA]AA-(Positive) / [ICRA]A1+;	Oct-24-2024	[ICRA]AA-(Positive) / [ICRA]A1+;	-	-	Sept-9-22	[ICRA]AA-(Stable)
Non-fund based limit	Short term	23.31	Dec-04-2025	[ICRA]A1+	Oct-24-2024	[ICRA]A1+	July-26-2023	[ICRA]A1+	Sept-9-22	[ICRA]A1+
ST – Fund-based – WCDL- Interchangeable	Short term	(20.00)	Dec-04-2025	[ICRA]A1+	Oct-24-2024	[ICRA]A1+	-	-	-	-

Complexity level of the rated instruments

Instrument	Complexity indicator
Working capital	Simple
Term loan	Simple
Non-fund based limit	Very Simple
ST – Fund based – WCDL - Interchangeable	Simple
Unallocated limit	Not applicable

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click here](#)

Annexure I: Instrument details

ISIN	Instrument name	Date of issuance	Coupon rate	Maturity	Amount rated (Rs. crore)	Current rating and outlook
NA	Working capital	NA	NA	NA	240.00	[ICRA]AA- (Positive)
NA	Term loan*	-	-	-	60.00	[ICRA]AA- (Positive)
NA	Non-fund based limit	NA	NA	NA	23.31	[ICRA]A1+
NA	ST - Fund based – WCDL - Interchangeable	NA	NA	NA	(20.00)	[ICRA]A1+
NA	Unallocated limit	NA	NA	NA	10.0	[ICRA]AA-(Positive) / [ICRA]A1+;

Source: Company

*Proposed

[Please click here to view details of lender-wise facilities rated by ICRA](#)

Annexure II: List of entities considered for consolidated analysis

Company name	RBL ownership	Consolidation approach
Buzil Rossari Private Limited	100.00%	Full consolidation
Rossari Personal Care Products Private Limited	100.00%	Full consolidation
Unitop Chemicals Pvt. Ltd.	80.00%	Full consolidation
Tristar Intermediates Private Limited	100.00%	Full consolidation
Romakk Chemicals Private Limited	50.10%	Equity method
Hextar Unitop SDN BHD*	50.00%*	Equity method

Source: Company; *Holding by Unitop Chemicals Pvt Ltd

ANALYST CONTACTS

Girishkumar Kadam

+91 22 6114 3441

girishkumar@icraindia.com

Prashant Vasisht

+91 12 4454 5322

prashant.vasisht@icraindia.com

Anubha Rustagi

+91 22 6169 3345

anubha.rustagi2@icraindia.com

Meet Mehta

+91 22 6169 3364

meet.mehta@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar

+91 22 6114 3406

shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

HELPLINE FOR BUSINESS QUERIES

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

ABOUT ICRA LIMITED

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited




Registered Office

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001

Tel: +91 11 23357940-45



Branches



© Copyright, 2025 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.